RESEARCH & TREATMENT

Three-quarters of CAC2 member organizations fund essential research projects related to childhood and AYA cancer.  The coverage is deep and broad:  across the spectrum of development, from basic research through to clinical trials; across a wide range of topics, including data sharing, crucial medicines, psycho-social standards, and survivorship; and across the country and around the world.

Research funded by our members is crucial to discovering more effective treatments that minimize side effects and increase quality of life during and after treatment.  Most importantly, that research investment represents a shared aim to find cures for all types of childhood cancer.  CAC2 celebrates each and every member’s efforts to help close the large and persistent gap between funding needs to achieve this goal andavailable resources.

CAC2 doesn’t just applaud our member’s individual efforts but strives to act as a catalyst for research members to work collaboratively to effect positive change in the childhood cancer research community.  The Research and Treatment Interest Group has a four-pronged strategy for achieving this goal.

Research and Treatment Interest Group Strategy

Webinars, Conferences, and News
Information Repositories
Co-Funding Opportunities
Ethics and Best Practices

The Research and Treatment interest Group strives to establish CAC2 as a credible resource for moving the field of pediatric cancer forward through thoughtful, progressive studies and projects.

ALL member organizations with a research interest or focus are encouraged to participate in the work of the CAC2 Research and Treatment Interest Group. Volunteers are welcome to join a committee on a rolling basis. Please contact us at  for more information.

“Talent wins games, but teamwork and intelligence win championships.” – Michael Jordan

Ethics Think Tank
Foundation Match
ICRP Database
CAC2 Research Conference Proceedings
Research News

Latest CAC2 and Community News

CAC2 Childhood Cancer Community News Digest (May 20-26)

Assorted News from the Last Week: The FDA Pediatric ODAC met to "discuss perspectives on the impact of FDARA on the field of pediatric oncology, considerations related to implementation of FDARA for new molecularly targeted drugs and biological products, and ...

Community News–Health Subcommittee Markup in the House Energy & Commerce Committee Advances Legislation for Children with Cancer

The Energy and Commerce Committee advanced proposals earlier this month that will extend Americans’ access to telehealth services, strengthen and preserve Medicaid, and encourage innovation to help children with rare diseases. In a Subcommittee markup, the Health Subcommittee forwarded 21 ...

CAC2 Childhood Cancer Community News Digest (May 13-19)

Assorted News from the Last Week: St. Jude survivorship portal and its ability to facilitate breakthroughs in pediatric cancer survivorship research were published recently in Cancer Discovery. The portal integrates data involving whole genomic sequencing, treatment exposure and outcomes — creating ...